Targeting TCTP with sertraline and thioridazine in cancer treatment

Robert Amson, Christian Auclair, Fabrice André, Judith Karp, Adam Telerman

    Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

    18 Citations (Scopus)

    Abstract

    We have initially demonstrated in knocking down experiments that decreasing TCTP in cancer cells leads in some tissues to cell death while in others to a complete reorganization of the tumor into architectural structures reminiscent of normal ones. Based on these experiments and a series of other findings confirming the key role of TCTP in cancer, it became important to find pharmacological compounds to inhibit its function, and this became for us a priority. In the present text, we explain in detail the experiments that were performed and the perspectives of sertraline in cancer treatment, as this became today a reality with a clinical study that started in collaboration with Columbia University and Johns Hopkins University.

    Original languageEnglish
    Title of host publicationResults and Problems in Cell Differentiation
    PublisherSpringer Verlag
    Pages283-290
    Number of pages8
    DOIs
    Publication statusPublished - 1 Jan 2017

    Publication series

    NameResults and Problems in Cell Differentiation
    Volume64
    ISSN (Print)0080-1844
    ISSN (Electronic)1861-0412

    Cite this